Key Highlights

  • Indaptus Therapeutics closed at $2.85 on October 15, up 28.96%.
  • Indaptus Therapeutics is a clinical-stage biotechnology company.
  • Healthcare drew defensive buying as AI and chip shares sold off.
  • The prior close was about $2.21.

Indaptus Therapeutics (NASDAQ:INDP) was among the gainers in the Thursday, October 15, 2026 US regular session, closing at $2.85 for an advance of 28.96% on the day. The move came in a market that was otherwise dominated by a steep sell-off in AI-linked and semiconductor shares, and it placed Indaptus among the many small healthcare and biotechnology names that pushed higher while much of the technology complex fell. The most grounded reading therefore rests on the stock’s micro-cap, low-float characteristics set against the day’s defensive bid for healthcare, rather than on any assumed corporate development.

Indaptus and the Healthcare Bid

Indaptus is a micro-cap biotechnology company working in immuno-oncology, a field focused on harnessing and directing the body’s immune system against cancer. That area has attracted sustained scientific and investor attention, and it is home to a wide range of companies at varying stages of development. Indaptus sits at the smaller end of that landscape, and its position as a micro-cap name is central to understanding how its shares behave on any given day. Companies of this size typically trade with a limited public float, meaning the pool of shares readily available for buying and selling is modest, and structural feature has a direct bearing on the magnitude of its price swings.

A limited float is the clearest lens through which to view Thursday’s action. When relatively few shares are available to trade, comparatively small shifts in demand can produce outsized percentage moves, and sensitivity cuts in both directions. A single-session gain near twenty percent, while notable, is well within the range of what low-float micro-cap biotech names routinely produce, and it does not by itself point to a discrete piece of news. In the absence of a confirmed catalyst, the trading mechanics of a thinly traded stock offer the most reasonable explanation for the scale of the move.

The session’s broader character provided a supportive environment for healthcare names as a group. Thursday was defined by a deepening retreat in technology and chip shares and a rotation into defensive sectors, with healthcare among the areas that drew buying as investors stepped back from AI-related risk. That defensive bid set a constructive tone across much of the healthcare and biotechnology complex, and smaller names throughout the group tended to attract interest as capital sought shelter from the technology rout. Indaptus’s advance fits within that theme, even though the sector rotation functions as a backdrop rather than a precise explanation for any single stock’s individual move.

Indaptus in Context

A move of this size in a micro-cap immuno-oncology name can occur simply because of thin trading conditions and sentiment, particularly on a day when the broader market was directing capital toward defensive healthcare exposure.

For investors examining a name like Indaptus, the practical point is that micro-cap biotechnology shares tend to be highly volatile and can reverse sharp gains just as quickly as they post them. Together, those elements frame the advance as a low-float move amid a broad bid for healthcare.